Heather Colley

Heather Colley

Auto-generated profile, based on publicly available information

Heather Colley

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Vaccine
Verified
Journal Article
Closed access
MIMartha Iwamoto
Martha Iwamoto
CHCarole J. Hickman
Carole J. Hickman
HCHeather Colley
Heather Colley
RARobert J. Arciuolo
Robert J. Arciuolo
CMChristine E. Mahle
Christine E. Mahle
JRJennifer B. Rosen
Jennifer B. Rosen

27 March 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
CLChelsea S Lutz
Chelsea S Lutz
HNHuong Q Nguyen
Huong Q Nguyen
DMDavid L McClure
David L McClure
NMNina B Masters
Nina B Masters
MCMin-hsin Chen
Min-hsin Chen
MMMona Marin
Mona Marin
Background: In the United States, 2 doses of measles-mumps-rubella (MMR)–containing vaccines are recommended routinely during childhood; a third dose may be given under certain circumstances. We present observed seroprotection rates and estimate long-term dynamics of measles, mumps, and rubella neutralizing antibody (nAb) levels among 2- and 3-dose MMR (MMR2 and MMR3, respectively) vaccinees. Methods: Persons who received MMR2 at age 4–12 years or MMR3 at age 18–31 years were enrolled in 1994–1995 and 2009–2010, respectively. Per cohort, sera were collected before vaccination (baseline) and at various intervals ranging from 1 month to 10 years postvaccination to assess nAb levels. Annual changes in nAb levels per virus and cohort were estimated through 10 years postvaccination using generalized estimating equations. Models were stratified by baseline nAb levels. Results: Among MMR2 participants (n = 621), 93.7%, 73.4%, and 83.9% had protective nAb levels against measles, mumps, and rubella, respectively, at the 10-year visit; among MMR3 participants (n = 665), 90.5%, 69.1%, and 100% had protective nAb levels, respectively, at the 9–11-year visit. Estimated nAb levels declined annually across both cohorts, all viruses, and baseline nAb strata, though patterns and magnitude varied. More than one-quarter of participants had mumps nAb levels below the presumed seroprotection threshold at the terminal visits. Conclusions: These findings indicate that even when MMR antibodies wane, protection against disease is largely retained. Waning of mumps antibodies was greater than for measles and rubella in both 2- and 3-dose vaccinees, likely because a greater proportion failed to mount a robust initial response.

17 June 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSun B Sowers
Sun B Sowers
NCNakia S Clemmons
Nakia S Clemmons
SMSara Mercader
Sara Mercader
LNLindsey Nielsen
Lindsey Nielsen
HCHeather Colley
Heather Colley
CHCarole Hickman
Carole Hickman
Background: In 2017, a mumps outbreak occurred in a US military barracks. Serum collected at service entry was used to compare pre-exposure with presumptive vaccine-induced antibody levels from persons who developed mumps (cases) and potentially exposed persons who did not develop mumps (non-cases). Sufficient information to determine levels of exposure during the outbreak was not available. Methods: Pre-outbreak serum samples from the Department of Defense Serum Repository were available from 254 potentially exposed service members. Twelve developed clinical symptoms and had post-outbreak serum collected. All sera were tested with a mumps-specific enzyme immunoassay for immunoglobulin M, immunoglobulin G (IgG), and IgG avidity. The neutralizing antibodies to vaccine strain (Jeryl Lynn [JL], genotype A) and wildtype virus (genotype G) was assessed by a plaque reduction neutralization test. A Fisher exact test and receiver operator characteristic curve were used to analyze the antibody response for non-cases and mumps cases. Results: Eight mumps cases were laboratory confirmed. Pre-outbreak neutralizing antibody titers to JL and genotype G mumps virus and pre-outbreak IgG index values were proportionately lower for most cases as compared with exposed non-cases. When compared with potentially exposed non-cases, cases with clinical symptoms had greater odds of having a pre-outbreak JL titer <41 and a genotype G titer <16. Conclusions: We identified potential correlates of protection for mumps neutralizing antibody titers against JL and genotype G mumps viruses.

8 December 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
SSSun B Sowers
Sun B Sowers
HNHuong Q Nguyen
Huong Q Nguyen
NMNina Masters
Nina Masters
SMSara Mercader
Sara Mercader
HCHeather Colley
Heather Colley
SCStephen Crooke
Stephen Crooke
Background: A third dose of measles, mumps, and rubella vaccine (MMR3) may be administered in outbreak and nonoutbreak settings. However, data on long-term immunogenicity to the mumps component of MMR are limited. We examined durability of mumps antibody response among adults up to 11 years after receipt of MMR3. Methods: Persons who received MMR3 at ages 18–28 years had sera collected before (baseline), 1 month, 1, 5, and 9–11 years after vaccination. Mumps antibodies were assessed by plaque reduction neutralization, immunoassay (EIA), and immunoglobulin G (IgG) avidity. Neutralizing antibodies were assessed against the vaccine strain (Genotype A) and a wild-type virus from Genotype G. Participants with neutralizing antibody titers <31 for Genotype A and <8 for Genotype G, and with EIA index values <1.10 were considered potentially susceptible. Results: Among participants with data for all visits after MMR3 (40%, n = 262/655), susceptibility based on Genotype A titers increased from 15.7% (41/262) at baseline to 30.5% (80/262) 9–11 years after vaccination while susceptibility based on Genotype G titers remained relatively stable (30.2%–24.2%). The proportion of participants seronegative for mumps IgG by EIA increased from 0% (0/255) at baseline to 7.5% (19/255) 9–11 years after vaccination. The avidity index increased from 52% to 67% through Year 5 (P < .0001). Conclusions: By 9–11 years after receipt of MMR3, many participants had mumps antibody levels that predicted susceptibility to infection, comparable to those observed before receipt of MMR3. The antibody titers to Genotype G remained consistently lower than the titers to the vaccine strain.

27 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
JFJennifer J Fowler
Jennifer J Fowler
AMAmanda Metz
Amanda Metz
MBMeghan Barnes
Meghan Barnes
SGShannon L Gearhart
Shannon L Gearhart
TFThomas Daniel Filardo
Thomas Daniel Filardo
AGAlida M Gertz
Alida M Gertz
Background: Travelers who fly on commercial aircraft while infectious with measles are reported to the US Centers for Disease Control and Prevention (CDC) by health departments. CDC contacts airlines to collect information on potentially exposed travelers. Traveler locating information is shared with health departments to facilitate aircraft contact investigations. In May 2025, CDC was notified of a traveler who flew from Europe to Colorado while infectious with measles, transited through Denver International Airport, then flew from Colorado to North Dakota. This report describes details of the subsequent contact investigations, environmental assessment, and laboratory testing results. Methods: CDC laboratories conducted testing on a majority of case samples. Data from the CDC laboratory, CDC's Port Health Activity Reporting System, and health department investigations were analyzed to describe the index case, contacts, test results, and travel details. Flight records and visual inspection were used to describe relative locations of index and secondary case-patients at Denver International Airport. Results: The index case was in an unvaccinated adult. Aircraft contact investigations identified 135 exposed domestic travelers. Fifteen secondary cases were identified among people exposed during the international (5) and domestic (3) flights and at the airport (7). Two tertiary case-patients were also identified. Five of the secondary case-patients had at least 1 documented prior measles vaccination. Conclusions: Measles transmission may occur during travel. Measles vaccination is recommended prior to international travel for all travelers aged 6 months or older. Travelers with fever and other overt signs of transmissible illness, such as coughing or malaise, should be strongly encouraged to delay travel while symptomatic.